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Abstract
Genome-wide maps of DNase I hypersensitive sites (DHSs) reveal that most human promoters contain perpetually active cis-
regulatory elements between 2150 bp and +50 bp (2150/+50 bp) relative to the transcription start site (TSS). Transcription
factors (TFs) recruit cofactors (chromatin remodelers, histone/protein-modifying enzymes, and scaffold proteins) to these
elements in order to organize the local chromatin structure and coordinate the balance of post-translational modifications
nearby, contributing to the overall regulation of transcription. However, the rules of TF-mediated cofactor recruitment to
the 2150/+50 bp promoter regions remain poorly understood. Here, we provide evidence for a general model in which a
series of cis-regulatory elements (here termed ‘cardinal’ motifs) prefer acting individually, rather than in fixed combinations,
within the 2150/+50 bp regions to recruit TFs that dictate cofactor signatures distinctive of specific promoter subsets.
Subsequently, human promoters can be subclassified based on the presence of cardinal elements and their associated
cofactor signatures. In this study, furthermore, we have focused on promoters containing the nuclear respiratory factor 1
(NRF1) motif as the cardinal cis-regulatory element and have identified the pervasive association of NRF1 with the cofactor
lysine-specific demethylase 1 (LSD1/KDM1A). This signature might be distinctive of promoters regulating nuclear-encoded
mitochondrial and other particular genes in at least some cells. Together, we propose that decoding a signature-based,
expanded model of control at proximal promoter regions should lead to a better understanding of coordinated regulation
of gene transcription.
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Introduction
DNase I hypersensitive sites (DHSs) mark ‘open’ chromatin
regions in the human genome [1]. When profiled at genome-wide
scale in many different tissues and cell types, DHS profiles reveal
that most human promoters (at the transcriptional start site, TSS)
remain in an ‘open’ chromatin state [2–4]. These ‘open’
chromatin areas center between 2150 bp and +50 bp relative to
the TSS (+1), although they could be larger depending on the
mode of transcription initiation and identity of the specific
promoter [2,5–8]. They are also flanked by nucleosomes heavily
modified with histone H3 lysine 4 dimethylation (H3K4me2) and
trimethylation (H3K4me3), which also remain largely invariant
across different cell and tissue types [2,9]. Together, therefore,
promoters (at the TSS) show a rather persistent chromatin
organization that is likely associated with control of basal
transcription [2,9–13]. In fact, 240 bp to +40 bp regions (also
known as ‘core’ promoters) generally act as entry sites for the pre-
initiation complex (PIC) [5,6,14], and 2150 bp to240 bp regions
(also known as ‘proximal’ promoters) contain abundant and
conserved cis-acting regulatory elements that contribute to basal
transcription [15–18].
The genome-wide profiling of transcription factors (TFs) and
cofactors (i.e. TF-associated factors that do not bind to DNA and
that often act as chromatin remodeling activities, histone/protein-
modifying enzymes, or scaffold proteins) has recently provided
valuable information that may change our understanding of how
chromatin organization is established in promoters. Proximal
promoters have been traditionally viewed as the main targets of
TFs in the human genome; however, most TF binding profiles
consistently reveal preferential binding to distal, rather than
proximal, genomic sites (e.g. [19–23]). In an apparent paradox,
many cofactors (such as histone/protein-modifying activities) often
show preferential binding to promoter, rather than distal, genomic
sites, which is more consistent with the traditional view that
promoters are the major recruiters of transcriptional regulators in
the genome [24–32]. In some cases, it has been proposed that
histone/protein-modifying activities may directly recognize pro-
moter-specific cis-regulatory elements, such as in the case of
JARID2 and KDM2A, which are two lysine demethylase activities
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(KDMs) that remove methyl groups from lysine residues and
directly recognize GC-rich sites [24,33,34]. GC-rich sites are
common at proximal promoters [35,36]. However, it is unclear
how a highly abundant TF at promoters, such as Sp1, which binds
with high affinity to GC-rich sites, functions to facilitate or
compete with the binding of these cofactors at these regions. The
same question stands for other abundant proximal promoter TFs
(e.g. [12,37–41]). It is also unclear the recruitment in most of other
cases in which histone/protein-modifying activities do not
recognize DNA. Together, preventing a clear picture of how TF
binding patterns relate to those of histone/protein-modifying
enzymes at promoter regions.
Here, we have analyzed 21,000 human promoters from
2150 bp to +50 bp relative to the TSS to investigate the role of
cis-regulatory elements and their cognate TFs in recruiting
histone/protein-modifying activities, particularly KDMs, to these
sites. Co-occurrence analysis of the most highly enriched of these
elements (here termed ‘cardinal’ motifs) confirms that they tend to
occupy these regions in patterns that are independent from one
another, thus suggesting the existence of promoter subclasses
based on the independent presence of these motifs. To validate this
model, we profiled NRF1 and subunit B of NFY (NFYB), which
constitutively recognize two of the most abundant cardinal
elements, NRF1 and NFY/CCAAT. Our data confirmed that
both ‘cardinal TFs’ (for recognizing cardinal motifs) occupy two
largely independent promoter subsets. Furthermore, we screened
for KDM activities that may selectively act via one TF but not the
other, finding that LSD1 acts as a specific and pervasive cofactor
of NRF1. We further explored the binding profiles of approxi-
mately 60 other cofactors reported in the literature, which resulted
in the identification of other strong cardinal motif-cofactor
signatures. Together, we propose that an important function of
cardinal cis-regulatory elements at promoter DHSs is to dictate a
selective regulatory code of histone/protein-modifying activities
and other cofactors that distinguishes promoter subclasses.
Intriguingly, each subclass shows qualitative and quantitative
differences with regard to the type and number of cofactors
recruited, thus suggesting that there is a complex regulatory layer
depending on the presence of cardinal elements that might
contribute to the chromatin organization and regulation of DHS
promoters.
Results
Poor co-occurrence among motifs highly enriched at
2150/+50 bp regions
To guide the discovery of new regulatory mechanisms acting via
core/proximal promoter regions, we analyzed 2150/+50 bp
regions (relative to the TSS) based on previous studies showing
that these genomic coordinates overlap with the center of DNase I
hypersensitivity in active human promoters [2], and accumulate
promoter-specific motifs [37,38,42–45]. We extracted ‘all’ 2150/
+50 bp regions in the human genome (n = 21,000; independently
of their chromatin state in a particular cell or condition) and
performed de novo motif discovery analysis. This analysis resulted in
the identification of nine highly enriched motifs, which we defined
as ‘cardinal’ cis-regulatory elements. As expected, these nine
elements included the TATA-box, as well as sequences recognized
by well know ubiquitous TFs common in promoters: Sp1/GC-
rich, NFY/CCAAT-box, ETS/GABP/NRF2, NRF1, CREB/
CRE-MYC/E-box, and YY1 (Figure 1A). We also identified two
cardinal motifs whose recognition by specific TFs has been poorly
established: Clus1 [37], which may act as binding site for the zinc
finger TF Kaiso/ZBTB33 [46]; and a sequence that we named
GFY (for general factor Y), which may act as a binding site for the
TFs Ronin/Hcf-1 and Zfp143/Rbp-J [46,47] (Figure 1A). Co-
occurrence analysis of these nine elements showed differential
patterns of co-enrichment. For example, each of these sequences
(with the only exception of YY1) showed a higher tendency to co-
exist with copies of itself than with copies of the other eight
cardinal elements within the same 2150/+50 bp region (see the
dark blue squares mostly in the diagonal in Figure 1B).
Therefore, our analysis indicates that 2150/+50 bp regions are
more likely occupied by a single type of element rather than by
fixed combinations of different cardinal elements. Only in the case
of the NFY/CCAAT-box and the Sp1/GC-rich motifs did we
observe high tendencies to co-occur (Figure 1B; summarized in
Figure S1A). In addition, we performed co-occurrence analysis
using experimentally defined promoter DHSs in breast cancer
MCF7 cells and derived essentially the same conclusion, although
positive co-occurrences between different cardinal motifs were
even less significant (Figure S1B).
To test the predictive value of these analyses we focused on
motifs other than TATA-box and Sp1/GC-rich because these two
are well documented in the literature. Thus we performed
chromatin immunoprecipitation followed by massively parallel
sequencing (ChIP-seq) using antibodies that recognize nuclear
respiratory factor 1 (NRF1, or alpha-PAL), which binds as a
homodimer to the NRF1 site [48] and the nuclear transcription
factor Y (NFY, or CBF), which binds as an obligatory heterotrimer
of NFYA, NFYB, and NFYC to the NFY/CCAAT site [49]. Based
on the computational analysis, we predicted that NRF1 and NFY
would only occasionally coincide at 2150/+50 bp regions
(Figures 1B and S1B). ChIP-seq analysis in MCF7 cells revealed
1,264 and 1,522 high confidence NRF1 and NFYB peaks,
respectively (Supplementary Tables S1 and S2), and as
expected, these peaks were found preferentially at promoter
regions (Figure S1C), particularly within 2150/+50 bp regions
(43–45%, Figure 1C), also at the center of DHS and at the
nucleosome-free or -depleted region (NFR/NDRs) (Figure 1D),
and being surrounded by nucleosomes containing H3K4me2 and
Author Summary
Human cells exploit different mechanisms to coordinate
the expression of both protein-coding and non-coding
RNAs. Elucidating these mechanisms is essential to
understanding normal physiology and disease. In our
attempt to identify new regulatory layers acting particu-
larly at proximal promoters, we have computationally
analyzed the genomic sequences located from 2150 bp to
+50 bp relative to the transcriptional start site (TSS), which
are often at the center of ‘open’ chromatin regions in
human promoters. We have confirmed the presence of a
series of cis-regulatory elements (here referred to as
‘cardinal’ motifs) that show a strong preference for these
short regions. Interestingly, these elements tend to act
independently rather than in fixed combinations. There-
fore, we propose that they confer unique regulatory
features to the human promoter subsets that contain each
of these particular elements. In agreement with this model,
we have identified a large repertoire of preferential
partnerships between transcription factors recognizing
cardinal motifs and their associated proteins (cofactors),
thus decoding a signature-based model that distinguishes
distinctive regulatory types of promoters based on cardinal
motifs. These signatures may underlie a new layer of
transcriptional regulation to orchestrate coordinated gene
expression in human promoters.
Decoding Genome-Wide Regulatory Rules at Promoters
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H3K4me3 (Figures 1D and S1D). We also performed analyses of
ChIP-seq datasets available in the literature (although in some cases
in other cell lines) and established a similar relationship between the
set of predicted motifs, the actual TF peaks, experimentally defined
DHSs, and the profiles of histone marks H3K4me2 and H3K4me3
(Figure S1E). Importantly, -returning to the case of NRF1 and
NFYB- both TFs rarely co-localized at 2150/+50 bp (,4%,
Figure 1E), consistent with our prediction. This low rate of co-
binding of NRF1 and NFYB did not substantially increase upon
examining wider promoter regions (7–8% between 2800 bp and
+200 bp, Figure S2A), thus confirming their apparent binding
antagonism in promoters across the human genome.
Since NRF1 and NFYB occupy only 25% and 18% of their
respective predicted sites at 2150/+50 bp regions (based on the
comparison of ChIP-seq data and computational prediction of
NRF1 and NFY sites), we could not exclude the possibility that
their poor co-localization may be a result of technical limitations
associated with the ChIP-seq assay. To assess this possibility, we
alternatively assessed genomic binding of NRF1 and NFYB using
the highly sensitive ChIP-DSL assay [50]. This assay, in contrast
to ChIP-seq, is a targeted approach that lacks the direct
amplification of ChIP’ed DNA (see Methods for more details).
Using the Hu20K array (which allows for the targeted testing of
,20,000 human promoters between 2800 bp and +200 bp
Figure 1. A series of cis-regulatory elements (here termed ‘cardinal’ motifs) are highly enriched at 2150/+50 bp relative to TSS (+1)
and may define different subsets of human promoters. (A) Most human promoters contain ‘open’ chromatin regions at 2150/+50 bp relative
to +1, or TSS. These regions are surrounded by heavily modified nucleosomes containing H3K4me2/3 (depicted in red in the vignette). We have
identified the most enriched cis-regulatory elements in these particular regions by de novo motif discovery analysis of n = 21,000 human promoters.
The panel shows rank of element enrichment, fraction of promoters containing these elements, consensus sequence, and cognate TF when known
(e.g. NRF1 or NFY) or when proposed (e.g. Clus1). We refer to these elements as ‘cardinal’ motifs, and to the TFs that recognize them as ‘cardinal’ TFs.
(B) Analysis of motif co-occurrences among cardinal motifs. Results are shown as a matrix of co-occurrences based on the analysis of n = 21,000
human promoters (2150/+50 bp). Co-occurrence log2 p-values are shown as a gradient of blue-to-red for positive-to-negative co-occurrences, and as
white in the absence of significant co-occurrence. (C) Positional binding analysis of cardinal TFs NRF1 (red) and NFYB (blue) with respect to 2150/
+50 bp genomic regions in MCF7 cells, based on ChIP-seq data. The x-axis refers to genomic distances with respect to 2150/+50 bp (center of the
panel). Genomic windows span: 200 bp (between 2150/+50 bp and 62 kb), 1 kb (between 62 kb and 610 kb), and the rest of distances together
(beyond 610 kb). The y-axis refers to percentage of the total of NRF1 and NFYB peaks in each genomic range. The total number of peaks (n) and the
specific number of peaks within 2150/+50 bp regions (n) are also indicated in the panel. (D) Meta-analysis of sequencing read density based on
DNaseI-seq (top) and H3K4me2 MNase-seq (bottom) around NRF1 (red) and NFYB (blue) ChIP-seq peaks (both at the center of the panel). (E) Venn
diagram depicting the overlap of RNA PolII (grey circle), NRF1 (red circle), and NFYB (blue circle) ChIP-seq peaks in MCF7 cells. We considered as
‘overlap’ the coincidence of NRF1 and NFYB peaks in the same 2150/+50 bp region. Also, we considered as ‘overlap’ the coincidence of RNA PolII
peaks within61 kb of a TSS containing NRF1 or NFYB peaks at 2150/+50 bp. (F) Functional (gene ontology, or GO) analysis of genes with NRF1 (top)
or NFYB (bottom) ChIP-seq peaks in their 2150/+50 bp regions. P-values (log scale) are shown in the x-axis. GO terms are indicated in the y-axis.
doi:10.1371/journal.pgen.1003906.g001
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relative to the TSS), we re-identified 63–73% of the NRF1 and
72–81% of the NFYB ChIP-seq-positive promoters (depending on
how stringently we defined a ChIP-DSL-positive hit: p,0.0001-
p,0.01; Figure S2B). Using the most stringent analysis
(p,0.0001), the ChIP-DSL assay identified large subsets of
NRF1 and NFYB positive promoters that were not identified by
ChIP-seq (1,320 and 1,525, respectively; Figure S2B), which
were also highly enriched in NRF1 or NFY/CCAAT motifs.
However, consistent with our ChIP-seq analyses, they showed
relatively poor NRF1 and NFYB co-localization (Figure S2C).
The only exception to this observation was a small subset of NRF1
and NFYB co-occupied promoters (n = 332, Figure S2C), in
which NRF1 and NFY/CCAAT motifs also co-occurred with
abnormal high significance (Figure S2D). Overall, therefore, our
ChIP-seq and ChIP-DSL results with NRF1 and NFYB confirm
the predictive value of our computational analysis, which suggests
that cardinal motifs (and their cognate TFs) tend to be present
independently rather than in fixed pairs within these regions. In
fact, combined analysis of the NRF1 and NFYB ChIP-DSL
datasets showed that almost 35% of all human promoters tested on
the Hu20K array contain one or the other TF, although they still
poorly coincide. We also performed gene ontology (GO) analysis
of genes associated with 2150/+50 bp NRF1 and NFYB ChIP-
seq peaks to associate them with biological functions. As expected,
based on the known functions of NRF1, genes associated with this
TF were linked to RNA processing and metabolism, translation,
mitochondria, and intracellular transport of proteins (Figure 1F,
top panel), whereas those associated with NFYB were linked to cell
cycle, regulation of transcription, and response to DNA damage,
among others (Figure 1F, bottom panel). Similar results were
obtained using the ChIP-DSL data (Figure S2E). Therefore, the
tendency to occupy different promoters may also be associated
with their specific biological functions.
Cardinal cis-regulatory elements dictate regulatory
signatures of histone-modifying enzymes
If many 2150/+50 bp regions could be distinguished by a
single cardinal cis-regulatory element and its cognate TF, then we
hypothesized that this element could also lead to selective
(distinguishable) recruitment of cofactors via TFs. To test this
hypothesis, we focused on KDMs because these histone-modifying
enzymes have been repeatedly shown to bind preferentially to
promoters in genome-wide tests [24,26–31], although their rules of
TF-mediated recruitment to promoters are poorly understood,
especially on a genome-wide scale [51,52]. In order to elucidate
the role of KDMs on NRF1- and NFYB-mediated transcription,
we tested the effects of short interfering RNA (siRNA)-mediated
depletion of KDMs on luciferase transcription under the control of
three canonical NRF1 sites (36NRF1-Luc) or three canonical NFY
sites (36NFY-Luc) in HEK293T cells (Figure 2A). Although these
sites are not in the context of endogenous promoters (thus results
should be taken with caution), this minimalist strategy ensures that
the only difference between these two promoters is the cardinal
motif. We tested 27 siRNAs that corresponded to the 27 KDMs
that are expressed in these cells (based on gene expression profiles),
out of around 30 encoded in the human genome. KDM specificity
for NRF1 or NFY sites was established by comparing the relative
effects of the same KDM siRNA treatment on NRF1- and NFY-
regulated luciferase transcription with respect to control siRNA
(Figure S3A). By performing these comparisons, we identified 13
siRNA treatments that had selective influences (p-value,0.05) on
luciferase transcription depending on whether the motifs were
NRF1 or NFY (summarized in Figure 2B). Six of these siRNAs
specifically altered 36NRF1-dependent transcription (Figure 2B,
top), while 8 siRNAs specifically affected 36NFY-dependent
transcription (Figure 2B, bottom). One siRNA treatment
(KDM5C siRNA) had significant effects on both 36NRF1- and
36NFY-dependent transcriptional units when compared to
siRNA control, but with opposite effect on each reporter. Three
other siRNAs (red/blue circles in Figure 2B) also induced
changes in the expressions of both reporters when compared to
siRNA control, however, these effects were in the same direction
and clearly more significant for one site over the other (p-
value,0.05 between them). Overall, 8 siRNA treatments induced
down-regulation of gene expression (Figure 2B, left), while 6
induced up-regulation compared to control siRNA (Figure 2B,
right), which may interestingly suggest that these cardinal motifs
impose a balance of positive and negative activities on the same
promoter, rather than an exclusive effect of a single activity. The
results of this analysis also suggest that 36 copies of the same
cardinal motif at 2150/+50 bp regions are sufficient to dictate a
rich and selective regulatory pattern of KDMs.
Because the results just described could be either the result of
direct or indirect effects, we capitalized on our specific result
revealing that LSD1 siRNA alters NRF1- but not NFY-motif
mediated transcription (Figure 2B, top and left) by using the case
of LSD1 to study cardinal motif-induced KDM regulatory
patterns in more detail. For our study, we performed ChIP-seq
analysis of lysine specific demethylase 1 (LSD1) in MCF7 cells,
identifying 3,690 high confidence peaks that showed high
preference for annotated promoter regions (Figure 2C, pie
chart). A full list of genomic locations can be found in
Supplementary Table S3. LSD1 shows its strongest binding
preference for the 2150/+50 bp region (42%, Figure 2C), at the
center of the promoter DHS and NFR/NDR (Figure S3B).
Surprisingly, this reveals that LSD1 is a genuine promoter DHS-
specific factor, similar to NRF1 and NFYB (Figure 1C). When
comparing the binding patterns of LSD1, NRF1, and NFYB, we
observed that virtually all NRF1-positive regions were occupied by
LSD1 (99%), with only a few NFYB-positive regions being
occupied by LSD1 if NRF1 was not nearby (4%, Figure 2D). We
also observed similar results for LSD1 promoter occupation using
the highly sensitive ChIP-DSL assay (Figure S3C), as well as a
high correlation of LSD1 binding with NRF1 on a genome-wide
scale (Figure S3D). In the context of a third ‘cardinal’ TF, Sp1,
we also observed a strong associative preference for LSD1
contingent on co-localization with NRF1 in a limited analysis of
,2,000 human promoters (Figure S3E). Not surprisingly, de novo
motif discovery analysis of LSD1 ChIP-seq peaks revealed
overwhelming enrichment of NRF1 sites (Figure S4A). We also
observed enrichment of the estrogen responsive element (ERE) in
agreement with our own previous studies showing that estrogen
receptor alpha (ERa) recruits LSD1 to ERa-regulated regions via
EREs [53]. However, the co-localization of ERa and LSD1 was
mostly found at distal (non-promoter or H3K4me3-negative) sites
(Figure S4B and S4C). In contrast, the co-association between
NRF1 and LSD1 was characteristic of promoter (or H3K4me3-
positive) regions (Figure S4C).
Next, we examined whether strong NRF1 and LSD1 co-
association is a cell type-specific feature. We performed LSD1
ChIP-DSL analyses in human mammary epithelial (HMEC),
prostate cancer (LNCaP), osteosarcoma (U2OS), and neuroblas-
toma (SH-SY5Y) cells. Our results showed significant NRF1 motif
enrichment in LSD1 peaks in all four examined cell lines, although
the levels of enrichment were slightly different among them
(Figure S5A). U2OS cells showed almost identical motif
enrichment to that observed in MCF7 cells (Figure S5A), and
more than 80% of the LSD1-positive promoters in these cells were
Decoding Genome-Wide Regulatory Rules at Promoters
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also LSD1-positive in MCF7 cells. Based on this finding, we
included U2OS cells in some of the experiments reported later in
this study. To confirm the high binding coincidence of LSD1 in
U2OS and MCF7 cells, we performed standard ChIP analysis on
random targets (Figure S5B), and on a few classic NRF1-
regulated promoters (Figure S5C), and observed almost identical
LSD1 binding patterns in both cell lines. The LSD1 binding
program has also been recently reported in mouse embryonic stem
cells (mESCs) [54], and although no particular connection
between LSD1 and NRF1 was highlighted in this study, we
analyzed the available data and observed that the NRF1 site is also
significantly enriched between -150 bp and +50 bp relative to the
TSS in these cells (p = 1e-42). In fact, the LSD1 binding map in
human MCF7 and mouse ESCs differs at many sites (which is
expected, especially at distal regions, since these two lines derive
from different organisms and are completely different in many
aspects [55]), but they show remarkably similar binding profiles at
many TSSs, including at those of classic NRF1 target promoters
(Figures S5D and S6). Taken together, our results show that the
strong co-association of NRF1 motifs, NRF1 TF, and the LSD1
cofactor at 2150/+50 bp regions can be observed in different cell
lines and organisms, which supports a model in which cis-
regulatory elements in these regions dictate strong and common
cofactor signatures.
Figure 2. Cardinal motifs dictate patterns of transcriptional regulatory activities. (A) Schematic overview of the siRNA-based screen to
identify lysine demethylase (KDM) activities that may act selectively via NRF1 or NFYB motifs. KDMs belong to two gene families: the family of amine
oxidase flavin (AOF)-containing domain proteins, and the family of Jumonji C (JmjC)-containing proteins. HEK293T cells were transfected with a
vector expressing the luciferase gene under control of three multimerized copies of NRF1 (36NRF1, left side of the scheme) or three multimerized
copies of NFY (36NFY, right side of the scheme). Luciferase levels were tested after independent treatment with n = 27 different KDM siRNAs, plus
controls. (B) Summary of siRNA-mediated effects that showed selectivity for 36NRF1 or 36NFY motifs in our screen. A total of n = 14 out of n = 27
siRNA treatments induced selective effects: n = 6 were selective of the presence of 36NRF1 (top), and n = 8 were selective of the presence of 36NFY
(bottom). Of these n = 14 siRNA treatments, furthermore, n = 8 induced down-regulation of the reported gene (left), and n = 6 induced its up-
regulation (right). Selectivity for 36NRF1 or 36NFY motifs was established by the direct comparison of siRNA-mediated effects induced by the same
siRNA treatment on 36NRF1- or 36NFY-luciferase ((p,0.05; last row in Figure S3A). In n = 11 out of the n = 14 treatments (red circles if selective of
36NRF1, or blue circles if selective of 36NFY), the difference between the specific KDM and control (scrambled) siRNA-mediated effect was also
statistically significant (p,0.05; first and second rows in Figure S3A). In the other n = 3 out of the n = 14 selective siRNA treatments (red-and-blue
circles), the difference with respect to control siRNA was statistically significant for both 36NRF1- and 36NFY-regulated units, although statistically
significant also when compared between them (p,0.05; last row in Figure S3A). (C) Positional binding analysis of LSD1 in MCF7 cells (as in
Figure 1C), and genomic localization of LSD1 ChIP-seq peaks with respect to the genome annotation (pie chart). The numbers included in the pie
chart refer to the fraction of LSD1 peaks associated with each annotated region. (D) Venn diagram depicting the overlap of LSD1 (orange), NRF1 (red),
and NFYB (blue) ChIP-seq peaks at 2150/+50 bp regions in MCF7 cells. We considered as ‘overlap’ the coincidence of NRF1, NFYB, and/or LSD1 peaks
in the same 2150/+50 bp region.
doi:10.1371/journal.pgen.1003906.g002
Decoding Genome-Wide Regulatory Rules at Promoters
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Cardinal TFs recruit ‘signature’ cofactors
Careful examination of LSD1 and NRF1 ChIP-seq peaks
revealed their very close alignment at specific loci (Figures 3A
and S7) and on a genome-wide scale (Figure 3B). To test
whether NRF1 (indirectly, the NRF1 motif) could be responsible
for recruiting LSD1 to a promoter region, we took advantage of
the same luciferase expression system that we previously employed
to test the involvement of KDMs in cardinal motif dependent
transcription (Figure 2A). For these experiments, we engineered
the construct containing the luciferase gene under control of
36NRF1 sites (36NRF1) to contain a sequence variant with point
mutations expected to disrupt binding of NRF1 (scheme in
Figure 3C, and Methods). Using the wild-type and mutated
reporter constructs, we observed that both the levels of luciferase
expression (measured by the luciferase assay) and NRF1/LSD1
binding (measured by standard ChIP) were completely dependent
on the presence of wild-type NRF1 motifs, suggesting that LSD1
acts via NRF1 sites as a consequence of direct recruitment by
NRF1 (Figure 3C). Also in support of this model, endogenous
LSD1 co-immunoprecipitated with endogenous NRF1 and vice
versa, whereas LSD1 did not co-immunoprecipitate with endog-
enous NFYB in the same cell extracts (Figure 3D). Size exclusion
chromatography of nuclear extracts also suggested that NRF1 and
LSD1 interact (directly or indirectly), since a pool of NRF1 co-
fractionates with a pool of LSD1 as part of what could be a ‘super’-
multiprotein complex of a molecular size larger than 2MDa
(Figure 3E). We also observed an additional pool of NRF1 and
LSD1 that co-fractionated in very slow elution fractions
(Figure 3E), but these fractions likely corresponded to elution
as individual molecules, rather than as physically associated
partners. Taken together, these results suggest that NRF1, via
NRF1 sites, could mediate the recruitment of LSD1 to promoter
regions, which is consistent with their strong co-association on a
genome-wide scale and in different cell types.
Functional association of NRF1 and LSD1
The almost pervasive association of NRF1 with LSD1 at 2150/
+50 bp regions does not directly imply a functional relationship
between them or, if such relationship exists, that it is functionally
universal at every single promoter. In fact, any functional
relationship between these two factors may be complex because
LSD1 may act as either a coactivator or corepressor of
transcription, depending on the context of its binding [56–60].
Our data obtained in the context of the 36NRF1 sites suggested
that LSD1 can act as coactivator of NRF1, at least under this
‘artificial’ condition (Figure 2B). To test this hypothesis on
endogenous NRF1 sites, we tested two classic NRF1 targets
(TFAM and FXR2) and three new NRF1/LSD1 targets uncovered
in this study (CDC42, CDC2, and SAP18). For these five genes, both
LSD1 and NRF1 knockdown resulted in decreased expression
when compared to control siRNA, suggesting that LSD1 is in fact
a coactivator of NRF1-mediated transcription (Figure 4A). To
test this possibility on a genome-wide scale, we performed whole-
genome expression profiling analysis following NRF1, LSD1, or
control siRNA treatment. We identified 2,351 genes as signifi-
cantly altered by NRF1 knockdown, and 1,091 genes as
significantly altered by LSD1 knockdown, both compared to
control siRNA. Of these genes, a very significant number of them
were altered by both LSD1 and NRF1 siRNA treatments (n = 518,
p-value,1.0E-10), or 22% and 47% of all NRF1 and LSD1 siRNA-
affected genes, respectively (Figure 4B). About 90% of these 518
genes were affected in the same direction by both treatments
(either up or down-regulated). Additionally, motif analysis of
the 2150/+50 bp regions associated with the NRF1 and LSD1
siRNA-altered genes showed high enrichment of NRF1 motifs,
thus supporting the idea that many LSD1-functionally regulated
genes (and obviously many NRF1-regulated genes) are bona fide
NRF1 motif-containing promoters (Figure 4C). We were initially
surprised that NFY/CCAAT motifs were also significantly
enriched in the NRF1 siRNA-altered genes (Figure 4C, left
panel), however, we suspect that this enrichment may derive from
the unexpected NRF1 siRNA-mediated up-regulation of NFYA and
NFYB genes (as determined by microarray), which are two
components of the trimer that constitutes NFY, thus potentially
affecting NFY/CCAAT motif-containing promoters indirectly.
Our genome-wide analysis supports the idea that NRF1 and
LSD1 co-regulate gene transcription, but to establish the
homogeneity or heterogeneity of this functional partnership we
classified the full set of genes altered by both siRNA treatments
into four classes: Class I included genes down-regulated by both
siRNA treatments (n = 193); Class II included genes up-regulated
by both siRNAs (n = 272); Class III included genes down-regulated
by NRF1 siRNA, but up-regulated by LSD1 siRNA treatment
(n = 35); and Class IV included genes up-regulated by NRF1
siRNA, but down-regulated by LSD1 siRNA (n = 18; Figure 4D).
We also organized those genes only affected by one siRNA
treatment into four classes (Classes V–VIII; Figure 4D). Next, to
establish which transcriptional output is more likely to be
associated with direct versus indirect NRF1/LSD1-dependent
effects, we calculated the enrichment of NRF1- or LSD1-occupied
promoters for genes in each class (based on ChIP-DSL data) and
compared this value to the enrichment of NRF1- or LSD1-
occupied promoters for genes not affected by NRF1/LSD1 siRNA
(which we defined as ‘background’). A ratio greater than one (.1)
with respect to background might be associated with a higher
frequency of direct effects mediated by the siRNA treatment, while
a ratio lower than one (,1) might be associated with a higher
frequency of indirect effects (since the rate of promoter binding in
this case is lower than that observed in background, i.e. in siRNA-
unaffected genes). Following our analysis, we observed that genes
down-regulated by both NRF1 and LSD1 siRNAs tend to show a
higher frequency of NRF1 and LSD1 binding at their promoters
than background (Figure 4E, Class I). In contrast, genes up-
regulated by both siRNA treatments tend to show a higher
frequency of LSD1, but not NRF1, binding at their promoters
(Figure 4E, Class II). The ratio obtained for genes down-regulated
by NRF1 siRNA and up-regulated by LSD1 siRNA suggests a
general enrichment in direct NRF1, but indirect LSD1 effects
(Figure 4E, Class III), while the ratio obtained for genes up-
regulated by NRF1 siRNA and down-regulated by LSD1 siRNA
suggests that both NRF1 and LSD1 affect these genes indirectly
(Figure 4E, Class IV). These results are consistent with the current
view that NRF1 binds to promoters to activate gene transcription
(Classes I, III, and VII), and that LSD1 either acts as a co-activator
(Classes I and V) or a co-repressor of transcription (Classes II and
VI). The only classes in which both NRF1 and LSD1 show a
tendency to co-bind are I, V, VI, and VII, thus suggesting that in
the context of the whole human genome, LSD1 may act as a
NRF1 coactivator in some cases (Class I), or remain inactive in
others (Class VII), at least under the experimental conditions that
we tested. Class VI represents an interesting case in which LSD1
may inhibit the NRF1 activity, thus LSD1 knockdown impairs the
negative effect on NRF1-mediated activation, but NRF1 knock-
down per se has no effect on gene expression under already the
condition of LSD1-mediated NRF1 inhibition. More difficult to
explain are the Class V promoters. In this case, it is possible that
other TFs (besides NRF1) may recruit LSD1 to these promoters,
even if NRF1 is present, thus resulting in LSD1-dependent genes
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that are associated with, yet functionally independent of NRF1.
Overall, this functional analysis suggests that even if a motif/TF/
cofactor signature is pervasive in promoters across the genome, the
functional relevance could be rather complex, thus emphasizing
that these signatures should not be interpreted as representative of
universal functional outcomes.
A collection of regulatory signatures associated with
cardinal motifs
Finally, we explored the existence of additional strong
partnerships associated with cardinal motifs. We analyzed a
number of ENCODE ChIP-seq experiments and data from
multiple sources to generate a heatmap of motif/cofactor
preferences at promoter regions (Figure 5A). As predicted by
our model, the set of TFs binding to the most highly enriched
cardinal elements show no significant preference for motifs other
than their cognate sites, thus suggesting that they bind with
preference independently and define subsets of promoters
(Figure 5A: Sp1 as cognate of GC-rich, GABPA as cognate of
ETS, and ZBTB33 as cognate of Clus1). Also as predicted by our
model, we observed that some cofactors show strong preferences
for single or only a few motifs, thus supporting the idea of cardinal
motif-associated cofactor signatures (Figure 5A and 5B). For
example, NRF1 motif-enriched promoters were distinctly associ-
ated with LSD1, but also with JARID1C/KDM5C, which is
consistent with the result that KDM5C siRNA treatment altered
the expression of the 36NRF1-luciferase construct in our screen
(Figure 2B). We also observed evidence for the preferential
binding to NRF1 sites by the histone/protein-methyltranferase
ESET, which has been reported to add methyl marks that can
later be specifically removed by LSD1 [53,61], thus suggesting a
particular signature of NRF1-LSD1-ESET. Other potential
Figure 3. Cardinal motif NRF1 dictates the recruitment of KDM LSD1 via TF NRF1. (A) Representative examples of ChIP-seq tracks showing
precise co-alignment of NRF1 and LSD1. These particular loci (ZWINT and LINS-ASB7) were selected as representative despite being rare examples in
which NRF1 binds nearby NFYB, but they should help to emphasize the good co-alignment between LSD1 and NRF1 using NFYB as reference. The
track of ChIP-seq data for H3K4me3 was also included as reference. Annotation of Ref-seq genes is included. (B) Meta-analysis of sequencing read
density of LSD1 ChIP-seq (orange) and NRF1 ChIP-seq (red) signals around NRF1 peaks (center of the panel). (C) Left: Scheme of two constructs
engineered to contain 36 wild-type NRF1 sequences (3xwtNRF1, as in Figure 2A) or 36mutated NRF1 sequences (3xmutNRF1) upstream the
luciferase reporter gene. Panels: Luciferase assay with 3xwtNRF1- or 3xmutNRF1-transected U2OS cells (left panel) and ChIP analyses of NRF1 and
LSD1 at 3xwtNRF1 and 3xmutNRF1 sites (middle and right panels, respectively). For ChIP analyses, two regions were amplified (labeled in the scheme,
left): one region covering 3xwtNRF1 or 3xmutNRF1 sites (depending on the construct), amplified with primers named as ‘site’; and the other region
covering a distal, control area (the same in both constructs), amplified with primers named as ‘ctl’. (D) Co-immunoprecipitation (IP) assay with the set
of antibodies indicated on top of the panel, and detection with the set of antibodies indicated in the left of the panel. (E) Size exclusion
chromatography (Superose 6) of nuclear extracts obtained from MCF7 cells. Analysis of elution fractions by Western blot using anti-LSD1 (top) and
anti-NRF1 (bottom) antibodies. On top of the Western blot, elution of known molecular size markers is indicated (arrows). Voided volume was
determined with Blue Dextran 2000 (.2MDa).
doi:10.1371/journal.pgen.1003906.g003
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partnerships with NRF1 are: the histone acetyltransferase, PCAF,
the ATP-chromatin remodeler, CHD7, the methyl-DNA binding
protein, MBD4, the histone/protein deacetylase (HDAC),
HDAC8, the E3 ubiquitin-protein ligase, RING2, corepressors
SUZ12 and NCoR, and the dimethyl arginine binding protein,
TDRD3 (Figure 5B). Some of these cofactors were distinctly
associated with NRF1 sites (for example, LSD1 and ESET), while
others were associated with other motifs (for example, CHD7 and
NCoR; Figure 5A). Perhaps, it was initially expected that those
motifs with higher number of associated cofactors were Sp1/GC-
rich and ETS motifs, because these are two of the top-most
enriched cardinal sequences (Figure 1A). However, using the
same argument, it was surprising to observe that few number of
cofactors were associated with NRF1, NFY, and CREB/E-box/
Figure 4. Diversity of functional outcomes associated with NRF1/LSD1 recruitment at 2150/+50 bp regions. (A) Left: Western blot
analysis of NRF1 and LSD1 in whole cell extracts obtained from MCF7 cells in which NRF1 or LSD1 (indicated on top) were depleted by siRNA. Actin is
shown as loading control. Scrambled (CTL) siRNA is included as control of transfection. Panels: RT-qPCR analysis of genes that have been identified in
this study as having promoters co-occupied by NRF1 and LSD1 (NRF1+ and LSD1+ targets). Gene names are indicated on top of each panel.
Treatments are indicated at the bottom. Scrambled (CTL) siRNA was used as control. The y-axis refers to normalized expression to levels of ACTB
mRNA. (B) Top: Western blot analysis as shown in A (left panel) but in U2OS cells. Bottom: Venn diagram depicting the overlap of genes affected by
NRF1 (light red circle) and LSD1 (orange circle) siRNA treatments with respect to control (CTL) siRNA in U2OS cells, based on microarray. The number
of total and category-wise genes affected by the treatments are indicated, as well as the statistical significance of the overlap. (C) Matrix of motif
enrichment of cardinal motifs in 2150/+50 bp regions of genes identified by microarray as affected by NRF1 (left) or LSD1 (right) knockdown in U2OS
cells. Enrichment levels were determined with respect to background frequencies of the same motifs in 2150/+50 bp regions. Motif enrichments
higher than background are shown as a gradient of blue, while motif enrichments lower than background are shown as a gradient of red. No motif
enrichment is shown as white. The number of promoters analyzed is also indicated. (D) Venn diagram depicting the overlap of microarray-identified
genes classified based on their type of response to NRF1 or LSD1 siRNA treatments. The numbers of genes in the overlaps are indicated, as well as the
numbers of genes that did not overlap and the total numbers. (E) Combined analysis of microarray and ChIP-based data. We combined microarray
results identifying NRF1 and/or LSD1 siRNA-mediated effects and ChIP-DSL data identifying NRF1 and/or LSD1 occupied promoters. Gene classes
based on (D). The y-axis refers to the relative enrichment over background in the number of genes that were affected by both NRF1 and LSD1 siRNA
treatments and that had promoters occupied by LSD1 (orange) and/or NRF1 (red; see text for more details). A ratio of ‘fold over background’ higher
or lower than 1 (.1 or ,1, respectively) distinguishes when a gene class contains a higher or lower frequency of either LSD1- or NRF1-occupied
promoters over the frequency observed in genes not affected by LSD1 or NRF1 siRNA treatments (which we defined as ‘background’). (F) As in E, but
for genes that were affected only by either NRF1 or LSD1 siRNA treatments.
doi:10.1371/journal.pgen.1003906.g004
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MYC motifs (Figure 5A), considering that their enrichment in
human promoters is comparable at least to that of ETS motifs
(Figure 1A). Overall, these data reveal that cardinal elements may
define strong cofactor signatures.
To also test the model of cardinal motif-cofactor regulatory
signatures experimentally, we engineered nine constructs to
contain NRF1 and/or NFYB motifs in the context of the sequence
of their ‘natural’ proximal promoter (2150/+50 bp), but upstream
the luciferase gene, and determined the effect on this gene of
depleting the same 27 KDMs that we tested in our original screen
with multimerized sites (Figure 2B). Three of these engineered
regions are targets of NRF1, but not NFYB; three are targets of
NFYB, but not NRF1; and three are targets of both (based on
ChIP-seq data, Figure S8A). According to our model, they should
show at least two main (or perhaps three, adding the case of mixed
NRF1-NFY promoters) basic patterns of KDM siRNA-mediated
Figure 5. Signature of cofactors associated with the enrichment of a specific cardinal motif. (A) Heatmap analysis of relative enrichment
of cardinal motifs in proximal promoter regions occupied by different proteins, based on .60 ChIP-seq datasets: n = 8 TF ChIP-seq datasets (labeled
in red) and n = 59 cofactors/others ChIP-seq datasets (labeled in black). Sources of ChIP-seq experiments: ENCODE (accession number and/or
laboratory are included in parenthesis); and NRF1, NFYB, and LSD1 datasets were generated in this study. The vector of motif enrichment for each
experiment was normalized and centered on the mean value to reveal the preferences of each experiment for cardinal motifs. The analysis shows
negative log of the hypergeometric p-value. (B) List of cofactors associated with each cardinal motif, based on (A). (C) Model of signatures of cofactors
associated with the presence of a specific cardinal motif (see text for details).
doi:10.1371/journal.pgen.1003906.g005
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effects as result of their cardinal NRF1 or NFY motif composition.
In fact, we observed that the global effects of the KDM siRNA
treatments on the three NRF1-driven promoters clustered
together, while the global effects of the same treatments on the
three NFY-driven promoters did the same (Figure S8B). Analyses
of the mixed promoters (whose alignment to the proposed model
was initially harder to predict) resulted in two of the promoters
clearly clustering with NRF1-driven promoters, while the third
promoter still clustered with them, but less clearly (Figure S8C).
Thus these results (based on a limited test) suggest that cofactor
signatures at promoters that contain a combination of cardinal
motifs resemble those of promoters with single cardinal motifs,
instead of representing a mix of effects induced by the individual
motifs, or showing a completely new regulatory signature. More in
general, this test with nine constructs reinforces our proposed
model that cardinal motifs are strong determinants of cofactor
signatures at proximal promoter regions.
Discussion
For decades, promoters have been known to be critically
important in gene transcription regulation [5,6,14]. Recently, new
approaches that allow analyses of chromatin structure at genome-
wide scale are adding new and more global perspectives to our
understanding of these regions. For example, these analyses reveal
that most human promoters are ‘open’ chromatin regions that
center between 2150 and +50 bp relative to the TSS, although
spread less intensively in slightly wider regions [2,9]. This finding
suggests that the bulk of TF binding and cofactor activities occurring
at promoters might be limited to these short genomic regions.
Consistent with this possibility, a recent functional analysis of 46
promoters indicated that regions immediately next to the TSS are
necessary but also sufficient to control basal transcription [62]. In an
effort to understand how these short regions operate on a genome-
wide scale, and more particularly to understand their mechanisms of
cofactor recruitment, we have explored the role of cis-regulatory
elements that are highly enriched at 2150/+50 bp in dictating the
recruitment of cofactors, in order to establish some basic rules. We
have termed these elements as cardinal motifs. Our studies suggest
that cardinal motifs tend to occupy 2150/+50 bp regions
independently rather than in fixed combinations, and that they
direct signatures of cofactor recruitment that allow us to classify
human promoters into subgroups based on these motifs and their
cofactor signatures (Figure 5C). The set of cardinal elements that
we have identified in our analysis of n = 21,000 human promoters is
not substantially different than that uncovered in previous
computational analyses [37,38,42–45]. Similarly, the poor co-
occurrence among these motifs in proximal promoter regions was
suggested in the past [37] (we show a direct comparison between our
analysis and this previous study in Figure S9A). Perhaps the major
differences between this report and this study are quantitative in
terms of motif co-occurrences (Figure S9A). With respect to the few
qualitative differences, this previous study identified an additional
motif, USF, which we did not find in our analysis; in contrast, this
previous study did not include the YY1 and GFY elements, which
we observe as highly enriched in our dataset (Figure S9A). These
differences might be explained in part by the facts that we used a
different algorithm and that analyzed a different number of
promoters and length of sequences in our tests (we studied
n = 21,000 human promoters between 2150 bp and +50 bp
relative to TSS, compared to n = 13,010 human promoters between
21,000 bp and +500 bp in the previous study). In any case, the
model and its functional implications were not experimentally tested
in this previous study, which is what we attempt here.
In a way, the model that cardinal motifs (or TFs) prefer acting
independently than in fixed combinations contrasts with the
observation that motifs (or TFs) often operate as combinations at
distal ‘open’ chromatin regions (i.e. enhancers and other genomic
elements; e.g. [20–23,63]). Therefore, the dominance of a single
cardinal motif at a single 2150/+50 bp region might be a feature
rather ‘exclusive’ of ‘open’ chromatin regions at promoters. Our
model, however, does not exclude the possibility that cardinal
motifs (via the TFs that recognize them) may act combinatorially
via short- or long-range interactions in the nuclear space, or in
trans, with other motifs (or TFs). It does not contradict either
previous reports indicating that cardinal motifs act synergistically
or cooperatively in many proximal promoter regions (e.g. [64–
68]). In fact, we may see this phenomenon in a significant number
of cases (e.g. see examples in Figures 3A and S7, and especially
Figure S2C and S2D). But we propose that these cases do not
represent the most general rule (Figures 1E and S2C).
Furthermore, we tested whether the preference to occupy different
promoter subsets is maintained if the margins of the promoter
sequence for analysis are wider (Figure S2A) or are defined
experimentally based on DHSs (Figure S1B), achieving the same
conclusion. We also tested whether this preference is maintained
when proximal promoters are subclassified based on the mode of
transcription initiation (‘focused’ or ‘dispersed’ [5,6]). In particu-
lar, we took advantage of available 59 RNA-seq data and identified
2,838 focused and 5,220 dispersed promoters in MCF7 cells (see
Methods for details). As expected, focused promoters show higher
preference to contain TATA and YY1 motifs (blue, Figure S9B).
Dispersed promoters show higher preference to contain ETS and
NRF1 motifs (red, Figure S9B). Despite these preferences, the
observed co-occurrences between TATA and YY1 or ETS and
NRF1 are not enriched within each group (Figure S9C).
What is the role of cardinal elements at proximal promoters?
Since 2150/+50 bp regions are at the center of promoter DHSs
[2], it is an interesting possibility that TFs recognizing these motifs
are responsible of the typical chromatin features of these regions
(‘open’ chromatin surrounded by nucleosomes that are heavily
modified). At enhancers, a special class of TFs termed ‘pioneer
factors’ have been suggested to contribute to their chromatin
organization [69]. Pioneer factors can be distinguished by their
ability to bind first in a temporal sequence of additional binding
events, and to bind independently rather than cooperatively to
chromatin [69]. Pioneer factors can also be distinguished since
they establish competence for gene expression, rather than activate
transcription [69]. Examples of pioneer factors include: lineage-
specific transcription factors, FoxA1/3 and GATA3/4. The fact
that cardinal TFs are often constitutively bound to the genome, as
pioneer factors FoxA1/3 and GATA3/4 at enhancers, and that
some of them remodel chromatin [70], makes them qualify as
candidate pioneer factors. If, furthermore, we consider our model
that cardinal TFs prefer binding independently to many promot-
ers, it would be a third property of pioneer factors. Thus TFs
recognizing cardinal motifs might be in fact ‘promoter-specific
pioneer factors’. However, we can only speculate on this
possibility, since other typical features of a pioneer factor, such
as be permissive for transcription rather than directly activate
transcription, and bind first in a sequence of binding events, are
not obvious in the case of cardinal TFs.
Based on: 1) our analysis of .60 ChIP-seq experiments
revealing that each cardinal motif might be associated with the
selective recruitment of a subset of cofactors (Figure 5A); 2) the
observation that knockdown analysis of a large panel of KDMs
shows that proximal promoters regulated by the same motif
exhibit relatively similar patterns of regulation (Figure S8); 3) that
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three copies of a single motif could dictate a complex regulatory
pattern of KDMs (Figure 2B); and, 4) that some cardinal TFs
strongly associate (biochemically and functionally) with specific
cofactors (e.g. NRF1 and LSD1); we propose here that a main role
of cardinal elements at proximal promoters is to dictate a signature
of cofactors. What is the functional relevance of dictating these
signatures? These cofactors may potentially be involved in
dictating the particular chromatin structure of these regions,
and/or control of transcription initiation and RNA PolII pause-
release. If that is the case, it is intriguing that two of these elements
(Sp1/GC-rich and ETS) account for most of the cofactor binding
preferences that we have identified in our analysis (see Figure 5B).
Initially, this observation may suggest that there are a series of
promoter subclasses of which we might not know much yet about
their regulation. However, it is also possible that our analysis of
cofactors was too restricted (limited to around 60 ChIP-seq
datasets), thus we may have specifically missed cofactors that are
associated with other cardinal motifs. It is also possible that ChIP-
seq data for those cofactors that are specifically associated with
cardinal motifs other than Sp1/GC-rich and ETS are not yet
available in the literature. For example, PGC1a is a cell type-
specific cofactor that is well known to regulate NRF1-dependent
transcription, but we did not find available ChIP-seq data for this
specific cofactor. But it is also possible that there is no bias in our
analyses or in the list of cofactors profiled up-to-date by ChIP-seq,
and that in fact there are two basic regulatory strategies for the
way cardinal motifs regulate transcription. For example, some
elements (such as Sp1/GC-rich and ETS) might be associated with
heavier promoter-dependent regulation, while other elements
(such as NRF1, NFY/CCAAT, CREB/MYC, and YY1) might be
subject to heavier enhancer/distal-dependent regulation, thus
revealing a genuine and essential regulatory difference between
these two groups. In fact, CBP is a well-known cofactor of CREB,
but CBP preferentially binds to distal sites, in contrast to CREB,
which preferentially binds to promoter regions [39], perhaps sin
agreement with this possibility. Further studies will be necessary to
elucidate a broader and clearer picture of the role of cardinal
elements in selective recruitment of cofactors.
Based on the relatively low number of cofactors we currently
know that act via cardinal motifs other than Sp1/GC-rich or ETS
(Figure 5B and 5C), our finding that the subset of promoters
dominated by NRF1 elements is strongly associated with LSD1 is of
special importance. LSD1 (also known as KDM1A, AOF2, and
BHC110) was the first KDM discovered [71]. LSD1 is a flavin
adenine dinucleotide (FAD)-dependent amine oxidase, which
requires FAD, an intermediate metabolite of the mitochondrial
respiratory chain, to remove methyl marks from histone and non-
histone proteins [71–73]. Interestingly, we have observed that the
‘NRF1/LSD1’ signature is associated with the control of nuclear-
encoded mitochondrial genes, which are also well-known NRF1
targets (Figures S5C, S5D and S6). Furthermore, genes in which
LSD1-acts as a coactivator of NRF1 (Class I in Figures 4D and
4E) show ‘‘mitochondrial’’ and ‘‘RNA processing’’ functions as the
most significantly associated GO terms (Figure S10A). Although
similar functions were also associated by GO analysis of genes
regulated (functionally) independently by NRF1 and LSD1 (Class
V and VII; Figures 4D, 4F, S10C, and S10E). In fact, it is
remarkable that LSD1 occupies an impressive 1/3 of all active,
nuclear-encoded mitochondrial genes in MCF7 cells (considering
only those promoters that are H3K4me3-positive or active in these
cells; Figure S10G). Similarly, an analysis of protein-protein
interacting networks of LSD1 peaks suggests that LSD1 regulates
‘‘mitochondrial metabolism’’, as well as ‘‘RNA metabolism/
translation’’ and ‘‘cell cycle’’ (Figure S11). Previous studies
already associated LSD1 to mitochondrial functions in fission yeast
(S. pombe) [74]. Moreover, it has been reported that the levels of
FAD modulate the switch to lipid storage in mouse adipocytes via
repressing PGC1b/PPARGC1B, PDK4, FATP1/SLC27A1, and
ATGL/PNPLA2 genes in an LSD1-dependent manner [75].
However, we did not find LSD1 at the promoters of these four
specific targets in MCF7 cells, and these genes were not expressed
in these cells (data not shown), perhaps suggesting an adipocyte-
specific, LSD1-dependent regulatory mechanism. In fact, mito-
chondrial regulation is not identical in every cell type, and the
content and morphology of mitochondria are largely determined
by nuclear-encoded genes of variable expression across tissues
[76,77]. In our analyses, LSD1 may also act as NRF1 negative
modulator (Class VI; Figures 4D and 4F), but this repressive
activity is associated with cell motility, signaling, and cell adhesion,
among other GO terms (Figures S10D). In summary, the
pervasive association between NRF1 and LSD1 cannot be
interpreted as associated with a single or universal functional
outcome, although when acting as NRF1 coactivator seems
strongly associated with control of mitochondrial metabolism and
biogenesis (Figures S12).
In MCF7 cells, we found that 76% of LSD1 peaks occur at or
near H3K4me3-marked regions, which corresponded to epige-
netically defined promoter regions (Figure S4C). This result is in
agreement with the finding that LSD1 is a component of the
.2MDa MLL1 complex [78], since MLL1 can also be found
associated to thousands of promoters in the human genome [79].
However, LSD1 does not seem to act dominantly via promoters in
every cell, which might be expected since LSD1 interacts with
many TFs in a cell-type-specific manner [53]. For example, the
binding map of LSD1 in erythromyeloblastoid leukemia K562
cells [3,30] only marginally overlaps with that in MCF7 cells (3%
at 2150/+50 bp), since most LSD1 binding in K562 cells is distal.
It is unclear to us why LSD1 binds strongly to promoters in MCF7
cells and other cell lines [53,80–82] (this can also be observed
using the datasets of others [54,83]), while in K562 cells it shows
poor association with promoter regions. We suspect that some cells
represent special cases, but this demands further exploration.
In conclusion, we propose a general model in which cardinal
cis-regulatory elements acting via promoter DHSs dictate the
selective recruitment of cofactors to specific promoters, thus
establishing a co-regulatory code that would be largely distinctive
of each cardinal motif and promoter subset defined by these
elements. We have started to decode this signature-based model,
but it will be necessary to identify the full repertoire of ‘regulatory
logic operations’ (as first defined in [84]) to have a complete
understanding of how these motifs function.
Materials and Methods
Cell culture and antibodies
Human breast cancer MCF7 cells were cultured in
DMEM(16)+GlutaMAX-I medium (Life Technologies) supple-
mented with 10% fetal bovine serum (FBS, Omega Scientific).
Human prostate cancer LNCaP cells were cultured in Advanced
DMEM/F12(16) medium (Life Technologies) supplemented with
10% FBS. Human osteosarcoma U2OS cells, human embryonic
kidney (HEK) 293T cells, and human neuroblastoma SH-SY5Y
cells were cultured according to The American Type Culture
Collection (ATCC) protocols. Primary normal human epithelial
cells (HMEC, CC-2651) were cultured using media and protocols
provided by Lonza Bioproducts, commercial supplier of these
cells. Cell lines were maintained in cell incubators at 37uC and 5%
CO2. MCF7, LNCaP, and HMEC cells were hormone-deprived
Decoding Genome-Wide Regulatory Rules at Promoters
PLOS Genetics | www.plosgenetics.org 11 November 2013 | Volume 9 | Issue 11 | e1003906
for 4 days in phenol-free plus charcoal-depleted FBS before each
experiment, and then treated 1 hr with 100 nM 17b-estradiol (E2,
Sigma-Aldrich) in the case of MCF7 and HMEC cells, or with
100 nM dihydrotestosterone (DHT, Sigma-Aldrich) in the case of
LNCaP cells, as previously reported [22,50,53]. Anti-LSD1
antibodies were previously described [53]. Anti-NRF1 (PAC102)
antibodies were a generous gift from Dr. Danny Reines [64]. Anti-
NFYB (H-209, sc-10779), anti-FoxA1 (C-20, sc-6553), anti-RNA
PolII (N-20, sc-899), and anti-ERa (HC-20, sc-543) antibodies
were purchased from Santa Cruz Biotechnology. Anti-H3K4me3
(07-473) antibodies were purchased from Upstate/Millipore. Anti-
actin (MAB1501) antibodies were purchased from Chemicon.
Source of promoter sequences and publically available
datasets
Core promoter sequences from 2150 to +50 bp relative to TSS
were extracted from the UCSC genome browser by using genome
assembly hg16 and mm3. 59 RNA-seq data from MCF7 cells is
available at the Database of Transcription Start Sites (DBTSS).
The following were the sources of DNaseI-seq, MNase-seq, ChIP-
seq, and ChIP-DSL data generated in previous studies and used
here: RNA PolII ChIP-seq in E2-treated MCF7 cells reported in
[85]; RNA PolII ChIP-DSL in E2-treated MCF7 cells reported in
[50]; ERa ChIP-seq in E2-treated MCF7 cells reported in [86];
DNaseI-seq and H3K4me2-MNase-seq in MCF7 cells reported in
[87]; LSD1 ChIP-DSL in E2-treated MCF7 cells reported in [53];
and LSD1 ChIP-seq in ESCs reported in [54]. Multiple datasets
were also generated by The ENCODE Project (as indicated in
figure legends). The rest of ChIP-seq and ChIP-DSL experiments
are reported in this study.
Identification and visualization of enriched cis-regulatory
elements
De novo motif discovery analysis was performed by HOMER
(http://biowhat.ucsd.edu/homer/), as described in previous
studies [22,23,27,50]. Motif enrichment at these regions was
determined in comparison to background regions randomly
selected from the genome matched for GC%. Sequence logos
were generated using the web-based application, WebLOGO
(http://weblogo.berkeley.edu). Motif enrichment heatmaps and
dendrograms were created by clustering Hypergeometric log P-
values using open source software Cluster (http://bonsai.ims.
u-tokyo.ac.jp/,mdehoon/software/cluster/software.htm#ctv).
Motif enrichment preference in cofactor ChIP-seq
datasets
For enrichment analysis of cardinal motifs in publically
available cofactor ChIP-Seq datasets, we first identified promoter
regions containing ChIP-Seq-identified cofactor peaks within
500 bp of the annotated TSS (we used peak lists provided by
the authors reporting each ChIP-seq dataset). We determined the
enrichment of each cardinal motif by HOMER in each set of
promoters (negative log of the hypergeometric p-value). The vector
of motif enrichment for each experiment was then normalized and
centered on the mean value to reveal the preferences of each
experiment for cardinal motifs.
Motif enrichment preference in focused and dispersed
promoters
To determine motif enrichment preferences of cardinal motifs
in promoters subclassified based on their mode of transcription
initiation, we took advantage of publically available 59 RNA-Seq
data obtained in MCF7 cells deposited in DBTSS. We defined
focused and dispersed promoters as having, respectively, $90%
and ,90% 59 RNA reads within 65 bp of the primary TSS
relative to the surrounding 100 bp promoter. This criteria
identified n = 2,838 (35%) focused and n = 5,220 (65%) dispersed
promoters in these cells. We then analyzed the preference of each
group to contain a specific cardinal cis-regulatory element by
HOMER.
ChIP and ChIP-seq assays
Chromatin immunoprecipitations (ChIPs) for standard RT-
qPCR analysis and ChIP-seq/DSL experiments were performed
as previously described [22,50,53]. RT-qPCRs for standard ChIPs
were conducted in an Mx3000P Real-Time PCR Instrument
(Agilent) with 26Brilliant qPCR Master mix (Stratagene). PCR
settings were the following: 10 min at 95uC followed by 40 cycles
of 95uC for 15 sec, 58uC for 15 sec, and 25 sec for 72uC. Primer
sequences were the following: FMR1-forward 59-CCAGGC-
CACTTGAAGAGAGA-39 and FMR1-reverse 59-TGCGGG-
TGTAAACACTGAAAC-39; TFAM-forward 59-ACCGGATGT-
TAGCAGATTTCC-39 and TFAM-reverse 59-CCTCCTGG-
CAATACACAACTC-39; FXR2-forward 59-CAAGGTTAGAG-
CCCCAGCTA-39 and FXR2-reverse 59-GCGGTGAAGAAAG-
AAGGCTA-39; GAPD-forward 59-TCCTCCTGTTTCATCCA-
AGC-39 and GAPD-reverse 59-TAGTAGCCGGGCCCTACT-
TT-39; and, UMODL1-forward 59-CCTTCAGTTCCCGGGAG-
TA-39 and UMODL1-reverse 59-CTGGAAGGAAATACGTC-
CACA-39. For ChIPs in plasmids, we engineered a construct with
36NRF1 sites upstream the minimal promoter in the pGL2
plasmid (see ‘siRNA screen’ for more details about this construct,
below) and a mutant 36NRF1 version that contains the following
fragment: 59-TGTTTATTTTCAGacgtacgtTGTTTATTTTCA-
GacgtacgtTGTTTATTTTCAG-39. Chromatin for ChIP to test
plasmids was prepared as for standard ChIPs. Analysis of ChIP-
seq experiments was previously described [22,23,27]. ChIP-seq
experiments were performed in an Illumina GA2 sequencing
instrument. DNA libraries were performed as previously described
[22,27]. Biological triplicates (n = 3) were pooled before DNA
library preparation. A full list of NRF1, NFYB, and LSD1 ChIP-
seq peaks can be found in Supplementary Table S1, S2, S3.
ChIP –DSL assay
ChIPs followed by DSL (DNA, Selection, and Ligation, or
ChIP-DSL) were performed and analyzed as previously described
[50]. Briefly, the ChIP-DSL assay uses ChIP DNA as a template
for oligonucleotide ligation, not for direct amplification. ChIP-
DSL is based on DNA-mediated isolation (or selection) of a pool of
pre-designed 40-mer oligonucleotides (plus T3 and T7 59 ends)
that are synthesized as pairs (T3+20-mer and T7+20-mer) but that
can be easily ligated once associated to their correct DNA template
in the genome, since both should anneal adjacently. Ligated
oligonucleotides can be then amplified after release from the
template based on the presence of T3 and T7 sequences. These
oligonucleotides are carefully pre-designed to anneal at similar
temperature and having similar GC content. In a typical ChIP-
DSL experiment, ChIP’ed DNA is purified and then randomly
biotinylated. Biotinylated DNA is incubated with the pool of DSL
(T3+20-mer and T7+20-mer) oligonucleotides before isolation
with streptavidine-coated beads. After extensive washing of excess
(not annealed) oligonucleotides, those annealed in to their right
DNA template can be ligated based on their close proximity. After
amplification, PCR fragments (all the same size, with similar
annealing temperature, and similar GC content) are hybridized to
an array of complementary sequences. We performed ChIP-DSL
experiments in triplicate (n = 3). For LSD1, NRF1 and NFYB
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ChIP-DSL analyses, we hybridized the samples onto the Hu20K
array, which contains 40-mer sequences for n<20,000 human
proximal promoters between 2800 bp and +200 bp (one
sequence per promoter). The experimentally calculated false
positive rate for a PolII ChIP-DSL experiment in MCF7 cells is
3%, and the false negative rate is 33% in the Hu20K array [50].
For Sp1 ChIP-DSL analysis, we hybridized the samples onto the
Hu2K array, which is a small version of the Hu20K array with
mostly promoters of cell cycle-regulated genes. As an additional
note, the numbers and percentages provided in the different
panels/figures with ChIP-DSL experiments were calculated based
on the actual number of spots on the array providing reliable
signal (e.g. n = 17,288 in the Hu20K array), not for the total
number of promoters actually spotted on the array (n = 20,000 in
the Hu20K array). A full summary of ChIP-DSL positive hits can
be found in Supplementary Table S4.
siRNA/plasmid transient transfection
All transient transfections (siRNAs and plasmids) were per-
formed with Lipofectamine 2000 following the manufacturer’s
protocol (Invitrogen). Transfections were performed one day after
seeding of cells, and the effects induced by the siRNA treatments
were measured after 2/3 days. Transient transfections in
HEK293T and U2OS cells were performed at 70–90% con-
fluency. Transient transfections in MCF7 cells were performed at
10–20% confluency. Specifically for the siRNA screen with
multimerized 36NRF1 or 36NFY sites and for the gene
expression analyses based on RT-qPCR and microarrays,
transient transfections were performed in 6-well plates. For the
siRNA screen with natural promoters and for transient transfec-
tions, experiments were performed in 96-well plates. In 96-well
plates, we transfected 8.67 pmols of siRNA (purchased from
Sigma-Aldrich), 0.1 mg of pGL2-Luciferase constructs (see below),
and 0.01 mg pRL(Renilla)-TK.
siRNA Screen and dual Luciferase/Renilla assay
We measured dual Luciferase/Renilla expression with the
Dual-Glo Luciferase Kit (Promega) using a Veritas Microplate
Luminometer (Turner Biosystems/Promega) and following stan-
dard procedures. Collected data were normalized (Firefly signal/
Renilla signal) and referred to the control (scrambled siRNA)
value. We engineered two constructs for the siRNA screen with
multimerized sites containing 36NRF1 or 36NFY/CCAAT sites
upstream the luciferase gene in the pGL2 plasmid harboring the
TK minimal promoter. The two cloned fragments were the
following: 59-TGCGCATGCGCAGacgtacgtTGCGCATGCGC-
AGacgtacgtTGCGCATGCGCAG-39, which contains three cop-
ies of the NRF1 site found in the FMR1 promoter (in uppercase)
[64]; and tctgATTGGctggttaaggcatctgcttaacttctgATTGGctggt-
taaggcatctgcttaactacgATTGGcta, which contains three copies of
a consensus NFY/CCAAT-box. For the siRNA screen with sites
in the context of their natural promoters, we engineered the
following regions upstream the luciferase gene in the pGL2-basic
plasmid:2153/+29 bp from the GDPD1 promoter,2158/+30 bp
from the ASNSD1 promoter, 2150/+50 bp from the ZBTB17
promoter, 2150/+50 bp from the ZNF695 promoter, 2150/
+50 bp from the STIP1 promoter, 2150/+50 bp from the
AKAP8L promoter, 2150/+37 bp from the ZWINT promoter,
2400/+50 bp) from the RFX1 promoter, and 2150/+100 bp
from the CCT3 promoter. These regions and their margins were
selected based on our NRF1 and NFYB ChIP-seq datasets, and
contain NRF1 peaks and recognizable NRF1 motifs (for GDPD1,
ASNSD1, ZBTB17), NFYB peaks and recognizable NFY/CCAAT
motifs (for ZWINT, RFX1, and CCT3), or NRF1 and NFYB peaks
and recognizable NRF1 and NFY/CCAAT motifs (for ZNF695,
STIP1, and AKAP8L). The position of the TSS was based on the
gene annotation in the UCSC browser. For data visualization of
the siRNA screen results with natural promoters, we represented
normalized luciferase signal in heatmaps created by clustering
Hypergeometric log values using Euclidean distance and average
linkage with TMEV 4.9 Software (Dana-Farber Cancer Institute).
RNA isolation, RT-PCR, and RNA profiling analysis
Total RNA was extracted with the RNeasy Kit (Qiagen) and
DNA was eliminated with on-colum DNase treatment (Qiagen)
following the manufacturer’s protocols. Total RNA was converted
into cDNA with the SuperScript First-Strand Synthesis Kit
(Invitrogen) following the manufacturer’s protocol. Real-time
PCR was conducted in a Mx3000P Real-Time PCR Instrument
(Agilent). Brilliant qPCR Master mix (Stratagene). PCR settings
were the following: 10 min at 95uC followed by 40 cycles of 95uC
for 15 sec, 58uC for 15 sec, and 25 sec for 72uC. Primer sequences
were the following: TFAM-forward 59-GTGATTCACCGCAG-
GAAAAG-39 and TFAM-reverse 59-CTGGTTTCCTGTGC-
CTATCC-39, FXR2-forward 59-AACCGTGGTAATCGGAC-
TGA-39 and FXR2-reverse 59-GGTGCAGGTTGGAGGTT-
TTA-39, for CDC42-forward 59-TACTGCAGGGCAAGAGG-
ATT-39 and CDC42-reverse 59-CCCAACAAGCAAGAAAGG-
AG-39, CDC2-forward 59-CCATGGGGATTCAGAAATTG-39
and CDC2-reverse 59-CCATTTTGCCAGAAATTCGT-39,
SAP18-forward 59-TGGATGCAACCTTGAAAGAA-39 and
SAP18-reverse 59-TGGAATCATCAGTCCCCTTT-39, and
ACTB-forward 59-GTGGGCATGGGTCAGAAG-39 and ACTB-
reverse 59-TCCATCACGATGCCAGTG-39. Cycle threshold
(Ct) values were extracted with MxPro qPCR Software (Agilent)
to calculate difference Ct (DCt) values with respect to control. For
microarray analysis, cDNA quality was assessed by the Agilent
Bioanalyzer (Agilent). Gene expression profiling was performed
using the Human Illumina Sentrix Expression BeadChips system,
as previously described [50] in the Biogem core (UCSD). Genome
expression data are available in the GEO database.
Co-immunoprecipitation assay
Co-immunoprecipitation (co-IP) experiments were carried out
as previously described [88]. Briefly, three 10 cm plates of
confluent MCF7 cells were washed with ice-cold PBS. Cells were
then disrupted and homogenized with IPH buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, with
Roche’s cocktail protease inhibitors). Samples were incubated on
ice for 20 min and cleared by maximum centrifugation (14,0006g)
for 10 minutes at 4uC. The supernatant volume was divided into
four aliquots for overnight incubation with specific antibodies.
Immuno-complexes were isolated after 2 hrs incubation with
protein A beads (Sigma-Aldrich). Protein A beads were then
pelleted and washed 3 times in IPH buffer. Protein A beads were
then resuspended in loading buffer and the solution was analyzed
by Western blot.
Size exclusion chromatography
Nuclear extracts from MCF7 cells were prepared fresh similarly
as in [89], with the following modification: nuclear pellet (after
discarding cytoplasmic and membranous fractions) was carefully
resuspended in nuclear extraction buffer (20 mM HEPES-KOH
pH 7.9, 25% glycerol, 400 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 dithiothreitol, 0.05% NP-40, and Roche’s cocktail
protease inhibitors) and maintained on ice for 40 min. The soluble
fraction was obtained after centrifugation for 10 min at 14,0006g
and 4uC. This fraction was then loaded onto a Superose 6 column
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(Pharmacia) previously equilibrated with nuclear extraction buffer
without glycerol. The column was applied into the FPLC system
and ran following manufacturer’s recommendations (Pharmacia),
as previously reported [90]. Elution fractions of 0.5 mL were
collected and analyzed by Western blot. Previously, we ran an
independent sample of proteins of known molecular sizes (HMW
or high-molecular weight Calibration kit, Pharmacia) to determine
elution volumes based on protein size and the size exclusion (void)
of the column. This set of proteins markers contained the
following: blue dextran (.2MDa), thyroglobulin (669KDa),
ferritin (440KDa), and catalase (232KDa).
Western blotting
Proteins were loaded and run on 4–12% Bis-Tris gels with MES
running buffer (Life Technologies). After transfer onto 0.2 mm-
pore PVDF (BioRad) or nitrocellulose (Whatman) membranes,
membranes were blocked with 5% milk/TBST for 30 min and
probed with antibodies diluted in 5% BSA/TBST overnight at
4uC. Immunodetection was achieved after incubation with HRP-
conjugated (Invitrogen) goat anti-mouse or goat anti-rabbit diluted
1:5,000 in blocking solution. HRP signal was detected by ECL
(Amersham-GE) and autoradiography film.
Functional gene annotation analysis
The analysis of functional gene annotations was performed
using the Database for Annotation, Visualization, and Integrated
Discovery (DAVID) 2.1 website [91]. We queried functional
annotations using official gene symbols. We selected genes for
analysis based on three different criteria: genes in which we
detected NRF1 or NFYB peaks at their 2150/+50 bp regions
relative to TSS based on ChIP-seq data; genes in which we
detected NRF1 or NFYB binding at their 2800/+200 bp regions
(p,0.0001) based on ChIP-DSL data; and genes affected by
different siRNA treatments (specified in figure panels) based on
gene expression microarrays. A representative selection of the
most enriched functional terms and the p-value of their
enrichment were extracted for visualization using Excel.
Network analysis
Networks of annotated biological functions associated with
LSD1 targets were constructed with open source Cytoscape
version 2.8.3 [92], and the following plugins: MiMI, which
integrates data from multiple databases [93]; MCODE, which
finds highly interconnected regions in a (sub)network [94];
NetworkAnalyzer, which computes and displays networks [95];
and Random Network, which generates random networks and
compare them to existing networks. We searched the following
databases: BIND, CCCB, DIP, GRID, HPRD, IntAct, KEGG,
MDC, MINT, PubMed, and Reactome. For visualization, we
show only interactions between query genes. List of network
attributes: gene name (closest gene to a LSD1 ChIP-seq peak),
Entrez gene ID, absolute distance from TSS (bases), peak genomic
localization annotation (promoter, intron, exon, TTS, intergenic),
and ChIP-seq signal (Tag counts). List of visualization parameters:
‘node color’ represents proximity to TSS (green gradient,
,400 bp; white, at 400 bp; red gradient, .400 bp); ‘node size’
represents ChIP-seq signal intensity; ‘node shape’ represents
genomic location annotation (promoter = circle; exon = rectangle;
intron = diamond; TTS = triangle; and intergenic = hexagon).
Sub-networks were generated with MCODE and those with the
highest score were selected. Network statistics were calculated
using NetworkAnalyzer plugin, which provides clustering coeffi-
cients for (sub)networks, and Random Network plugin, which
provides clustering coefficients for random (sub)networks. We
applied paired two-tailed t-test to compare (sub)network with
identical (same number of nodes) randomly generated (sub)net-
works.
Statistical analysis
Non-sequencing experiments were performed in triplicate
(including ChIP-DSL experiments), while sequencing experiments
were performed in triplicate but pooled before DNA library
preparation. Data is presented as mean 6 standard error of the
mean (s.e.m.) of replicates. Comparisons between two groups were
performed using paired two-tailed t-test. P-values,0.05 were
considered statistically significant. Additional information about
statistical analyses is provided in independent subsection (see
above).
Supporting Information
Figure S1 Cardinal motifs tend not to co-occur. (A) A summary
(manually drawn with PowerPoint) of positive (left) and negative
(right) motif co-occurrences identified in 2150/+50 bp regions,
based on Figure 1B. Connecting lines indicate a positive (black)
or negative (red) co-occurrence between two cardinal motifs, and
line thicknesses approximately correlate with levels of co-
occurrence. (B) Co-occurrence matrix of cardinal motifs in
n = 10,063 DHS regions defined experimentally by DNaseI-seq
in human MCF7 cells that overlapped with RefSeq promoters.
Co-occurrence log2 p-values are shown as a gradient of blue-to-red
for positive-to-negative co-occurrence, and as white for no
significant co-occurrence. (C) Distribution of NRF1 (left) and
NFYB (right) ChIP-seq peaks with respect to the genome
annotation. The numbers included in the pie charts refer to the
fraction of peaks associated with each annotated region. The total
number of peaks analyzed is also indicated. (D) Distribution of
sequencing read density, based on H3K4me3 ChIP-seq, around
NRF1 and NFYB ChIP-seq peaks (centre of the panel) in MCF7
cells. (E) Distribution of computationally predicted cardinal motif
densities (black) and sequencing read density of: TF ChIP-seq data
(red), DNaseI-seq data (light blue), H3K4me2 ChIP-seq data (light
green), and H3K4me3 ChIP-seq data (dark green) with respect to
TSS (vertical line at position 0). On top, the name of the specific
motif and TF (in parenthesis) analyzed is shown. Doted vertical
lines indicate 2150 bp and +50 bp positions. DNaseI-seq,
H3K4me2/3 ChIP-seq, NFYB ChIP-seq, GABPa ChIP-seq,
NRF1 ChIP-seq, and MAX ChIP-seq data were obtained in
MCF7 cells. Sp1, YY1, ZBTB33, and TBP ChIP-seq experiments
were obtained in K562 cells. Source of sequencing datasets: all but
H3K4me3, NRF1, and NFYB ChIP-seq experiments were
produced by ENCODE and are publically available.
(PDF)
Figure S2 Poor rate of colocalization between cardinal TFs
NRF1 and NFYB at 2150/+50 bp regions and beyond. (A) Venn
diagram depicting the overlap of NRF1 (red circle), NFYB (blue
circle), and RNA PolII (grey circle) in MCF7 cells. NRF1 and
NFYB data was based on ChIP-seq and peaks found between
2800 bp and +200 bp relative to TSS. We considered as ‘overlap’
the coincidence of NRF1 and NFYB peaks in the same 2800/
+200 bp region. Also, we considered as ‘overlap’ the coincidence
of RNA PolII peaks within 61 kb of a TSS containing NRF1 or
NFYB peaks at 28000/+200 bp. (B) Comparison of NRF1 (left)
and NFYB (right) ChIP-seq peaks and ChIP-DSL positive hits in
MCF7 cells. We compared the lists of 2800/+200 bp genomic
regions containing NRF1 or NFYB ChIP-seq peaks and the lists of
NRF1 or NFYB ChIP-DSL positive hits (or promoters) to
determine the number of coincident peaks/hits between both
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types of analyses. The analysis of ChIP-seq data was limited to the
set of genomic regions present on the Hu20K array. We compared
three levels of ChIP-DSL stringency based on p-values of positive
hits: p,0.01, p,0.001, and p,0.0001. The percentage and
number of promoters in each case are indicated. (C) Venn
diagram depicting the overlap of NRF1 (red circle), NFYB (blue
circle), and RNA PolII (grey circle) ChIP-DSL positive hits
(p,0.0001) in MCF7 cells. The ChIP-DSL assay limits the analysis
to 2800/+200 bp regions relative to TSS. (D) Matrix of motif
enrichment compared to background of the subset of n = 332
NRF1 and NFYB co-occupied promoters identified by ChIP-DSL.
Motif analysis limited to2150/+50 bp regions. Motif enrichments
higher than background are shown as a gradient of blue, while
motif enrichments lower than background are shown as a gradient
of red. No significant enrichment (equivalent to background) is
shown as white. (E) Functional or GO analysis of genes with
promoters occupied by NRF1 (left), NFYB (middle), or NRF1 and
NFYB (right) based on ChIP-DSL analysis (p,0.0001). Selected
GO terms are shown in the y-axis. The x-axis refers to p-values of
enrichment. Orange lines indicate p= 0.001.
(PDF)
Figure S3 Strong co-association between cardinal TF NRF1
and cofactor LSD1 at genome-wide scale. (A) SiRNA screen based
on the luciferase assay to identify KDMs (listed at the bottom) that
may act selectively via 36NRF1 sites (red) or 36NFY sites (blue).
A schematic overview of this screen and a summary of the results
are shown in Figure 2A and Figure 2B, respectively. Selectivity
for 36NRF1 or 36NFY sites is described in the figure legend of
Figure 2B. Bottom: P-values#0.05 are shown as grey boxes, p-
value.0.05 are shown as white boxes. (B) Distribution of
sequencing read density based on DNaseI-seq (top) and
H3K4me2 MNase-seq (H3K4me2-marked nucleosomes, bottom)
around LSD1 ChIP-seq peaks in MCF7 cells. (C) Venn diagram
depicting the overlap of LSD1 (orange), NRF1 (red), and NFYB
(blue) ChIP-DSL positive promoters in MCF7 cells based on the
Hu20K array (2800/+200 bp). (D) Venn diagram depicting the
overlap of LSD1 (orange), NRF1 (red), and NFYB (blue) ChIP-seq
peaks in MCF7 cells without restriction of genomic localization
(whole genome). (E) Percentage (top) and relative number (bottom)
of LSD1-occupied promoters in NRF1- (red), NFYB- (blue), or
Sp1- (green) occupied promoters in MCF7 cells, based on ChIP-
DSL data. The percentage (top) and relative number (bottom) of
LSD1-occupied promoters in cases that are not occupied by
NRF1, NFYB, or Sp1 are also shown (large square). Analysis
restricted to the n = 2,000 promoters present on the Hu2K array.
The top panel shows percentage of LSD1-occupation relative to
the total number of TF-positive promoters. The bottom panel
shows absolute numbers of the same analysis. Data for Sp1 ChIP-
DSL was obtained using the Hu2K array. Data for LSD1, NRF1,
and NFYB ChIP-DSL was obtained using the Hu20K array, but
their analyses were restricted to the set of promoters contained in
the Hu2K array. Note: the Hu2K array is mostly constituted of
cell cycle-regulated promoters, therefore, the percentages/fre-
quencies of occupied promoters by the different TFs/LSD1 in the
Hu2K array might be different than those observed in the analysis
of the ‘unbiased’ Hu20K array.
(PDF)
Figure S4 Strong co-association between LSD1 and NRF1 at
proximal promoters and between LSD1 and ERa at distal sites in
MCF7 cells. (A) Top-enriched motifs found in LSD1 ChIP-seq
peaks in MCF7 cells identified by de novo motif discovery analysis.
The panel includes: rank of motif enrichment, name of TFs
associated with each motif, and p-value of enrichment. (B) LSD1
binding at genomic regulatory regions of representative examples
of well-known ERa-regulated genes. The panel shows ChIP-seq
tracks for LSD1 (orange), NRF1 (red), NFYB (blue), ERa (light
green), FoxA1 (dark green), and H3K4me3 (black) at ERa-
regulated loci: TFF1, CTSD, and GREB1. Refseq annotations are
shown at the bottom of each panel. Coincident ERa and LSD1
peaks are enclosed in dotted boxes. (C) Heatmap analysis of LSD1,
H3K4me3, NRF1, and ERa ChIP-seq signal63 kb around LSD1
ChIP-seq peaks (center of the columns). Two sets of LSD1 peaks
were separately analyzed: LSD1 peaks nearby H3K4me3-marked
regions (i.e. promoters; on top); and, LSD1 peaks nearby
H3K4me3-negative regions (likely enhancers; at the bottom).
(PDF)
Figure S5 Strong binding co-association between NRF1 and
LSD1 in different cell lines/types. (A) Percentage of NRF1 and
NFYB occupied promoters that contain computationally predicted
NRF1 or NFY motifs (left and right panels, respectively) in MCF7,
HMEC, LNCaP, U2OS, and SH-SY5Y cells. Data based on
ChIP-DSL analysis. ‘Background’ corresponds to the fraction of
approximately 20,000 promoters in the Hu20K array that contain
predicted NRF1 or NFY motifs. (B) ChIP validation of randomly
selected LSD1 target promoters identified by ChIP-DSL in MCF7
cells (top), and ChIP analysis of the same promoters in U2OS cells
(bottom). The results are shown as binding fold change over IgG
signal. Three promoters were included as negative control (based
on ChIP-DSL experiments): LUC7L2, KIF11, and ESR1 promot-
ers. (C) ChIP analysis of well-known NRF1-regulated promoters
(FMR1, TFAM, and FXR2) and negative controls (GAPD and
UMODL1 promoters) in MCF7 and U2OS cells. NRF1 (left
panel), LSD1 (middle panel), and RNA PolII ChIP (right panel)
analyses are shown. (D) LSD1 (orange or green), NRF1 (red), and
H3K4me3 (black) ChIP-seq tracks in MCF7 cells (top) and mESCs
(bottom) for well-known NRF1-regulated promoters: TFAM (left
panel), FMR1 (middle panel), and FXR2 (right panel). LSD1 ChIP-
seq data in mESCs was obtained from Whyte et al., 2012. Refseq
annotation is shown at the bottom of each panel.
(PDF)
Figure S6 Binding of LSD1 to promoters of nuclear-encoded
components of the mitochondrial electron transport chain. Top,
left: scheme of multiprotein complexes involved in the electron
transport chain (ETC) in the inner mitochondrial membrane.
Panels: ChIP-seq tracks depicting loci of representative examples
of nuclear-encoded components of the mitochondrial electron
transport chain. LSD1 (orange or green), NRF1 (red), and
H3K4me3 (black) ChIP-seq tracks from MCF7 cells (three top
tracks) and mESCs (bottom track) are shown. LSD1 ChIP-seq data
in mESCs was obtained from Whyte et al., 2012. Refseq
annotation is shown at the bottom of each panel.
(PDF)
Figure S7 Fine co-localization of LSD1 and NRF1 in multiple
mammalian promoters. ChIP-seq tracks of representative loci
showing co-alignment of NRF1 (red) and LSD1 (orange) peaks.
These particular examples were selected from the small list of
promoters in which NFYB (blue) binds nearby NRF1 to help
emphasize the good co-alignment between LSD1 and NRF1 using
NFYB as reference. The H3K4me3 ChIP-seq track (black) is also
shown as reference. Refseq annotation is shown at the bottom of
each panel.
(PDF)
Figure S8 SiRNA-based screen in HEK293T cells to test KDM
siRNA-mediated effects on luciferase expression under control of
NRF1 and/or NFY motifs in the context of the sequence of their
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natural promoters. (A) Three sets of pGL2(basic) constructs were
engineered to contain NRF1 (left), NFY (right), or NRF1 and NFY
(middle) sites in the context of the sequence of their natural
promoter cloned upstream the luciferase gene. The specific
promoters were selected based on NRF1 and NFYB ChIP-seq
data in MCF7 cells (promoter/gene names are listed in the figure),
and all contain recognizable NRF1, NFY, or NRF1 and NFY
motifs. (B, C) Hierarchical clustering of luciferase levels relative to
control (scrambled) siRNA induced after the different siRNA
treatments (listed in the figure). Constructs are listed on top: those
containing NRF1 motifs are indicated by a red dot; while those
containing NFY motifs are indicated by a blue dot. In (B), it is
shown the clustering analysis of the three NRF1- and the three
NFY-regulated promoters. In (C), it is shown the clustering
analysis of the six promoters shown in (B) plus the three NRF1/
NFY-regulated promoters.
(PDF)
Figure S9 Distribution of cardinal motifs and analysis of motif
co-occurrences in promoters classified based on the mode of
transcription initiation. (A) Comparison of co-occurrence matrixes
of the seven cardinal motifs identified in this study (based on
n = 21,000 promoters and 2150/+50 bp regions; left panel) and
the most-enriched motifs identified in a previous analysis by
Fitzgerald et al., 2004 (based on n = 13,010 and 21,000/+500 bp
regions; right panel). The values of motif co-occurrence in the
right panel were directly derived from Fitzgerald et al., 2004. Co-
occurrence log2 p-values are shown as a gradient of blue-to-red for
positive-to-negative co-occurrences, and as white for no significant
co-occurrence. (B) Analysis of cardinal motif preferences for
promoters classified based on their mode of transcription
initiation: focused (left) and dispersed (right). Number of promoters
are indicated. We used 59 RNA-seq data in MCF7 cells obtained
from the DBTSS database (see Methods). The x-axis refers to log
p-value of enrichment, and the y-axis includes motif names. (C)
Co-occurrence matrixes of cardinal motifs in focused and
dispersed promoters identified in MCF7 cells. Co-occurrence
log2 p-values are shown as a gradient of blue-to-red for positive-to-
negative co-occurrence, and as white for no significant co-
occurrence.
(PDF)
Figure S10 Functional categories (GO terms) associated with
genes differentially expressed in LSD1 and/or NRF1 depleted cells.
(A–F) GO analysis of six of the eight classes of genes identified by
expression microarray (as shown in Figure 4D–4F) that were
affected by NRF1 and/or LSD1 siRNA treatments in U2OS cells:
genes down-regulated (A) or up-regulated (B) by both treatments
(Class I and Class II, respectively); genes exclusively down-regulated
(C) or exclusively up-regulated (D) by LSD1 siRNA (Class V and
Class VI, respectively); and, genes exclusively down-regulated (E) or
exclusively up-regulated (F) by NRF1 siRNA (Class VII and Class
VIII, respectively). The two remaining categories (Class III and
Class IV) do contain a number of genes that is too low for reliable
GO analysis (n = 18 and n = 35). (G) Analysis of NRF1 and LSD1
binding to active promoters regulating nuclear-encoded genes in
MCF7 cells. LSD1 and/or NRF1-positive promoters are shown in
the left cylinder, and LSD1 and NRF1-negative promoters are
shown in the right cylinder. There are three subcategories in the
first group: LSD1/NRF1 common-positive promoters (brown),
LSD1 only-positive promoters (orange), and NRF1 only-positive
promoters (red). Only H3K4m3-positive (active) promoters
identified by ChIP-DSL in MCF7 cells and regulating genes in
the category of ‘mitochondrion’ in the NCBI database were
included in this analysis (those promoters of genes expressed in
mitochondria, or H3K4me3-negative/inactive, or not present on
the Hu20K array were excluded). Data based on H3K4me3,
NRF1 and LSD1 ChIP-DSL experiments.
(PDF)
Figure S11 Protein interaction network of genes potentially
regulated by LSD1. Cytoscape analysis of gene products associated
with LSD1 binding in MCF7 cells (based on LSD1 ChIP-seq
data). Full network analysis is shown on top, and two of the five
high-score subnetworks are shown at the bottom. The full network
and these two subnetworks show a clustering coefficient that is
highly significant (p-value,0.001) compared with randomly
generated networks with the same number of nodes. The three
missing subnetworks in the figure included proteins that are
included within the subnetwork shown in the right bottom of the
figure. Functional categories are indicated next to each (sub)net-
work. Gene names are indicated inside each node. Node color,
node shape, and node size codes are indicated in the top right side
of the figure.
(PDF)
Figure S12 Summary of proposed NRF1-LSD1 functional
partnerships acting via 2150/+50 bp regions. This summary
only considers partnerships in which either NRF1 or LSD1, or
both (based on microarray analysis upon NRF1 and/or LSD1
siRNA treatments) are functionally active. It excludes, therefore,
the situation in which both NRF1 and LSD1 remain apparently
inactive (based on the observation of no-effects by microarray
upon NRF1 and LSD1 siRNA treatments). Classification (Class
number) based on Figure 4E and 4F. See text for more details.
(PDF)
Table S1 NRF1 ChIP-seq peaks identified in MCF7 cells.
Positions are expressed in hg18 coordinates.
(XLSX)
Table S2 NFYB ChIP-seq peaks identified in MCF7 cells.
Positions are expressed in hg18 coordinates.
(XLSX)
Table S3 LSD1 ChIP-seq peaks identified in MCF7 cells.
Positions are expressed in hg18 coordinates.
(XLSX)
Table S4 NRF1, NFYB, LSD1, and Sp1 ChIP-DSL positive
promoters identified in MCF7 cells. NRF1, NFYB, and LSD1
ChIP-DSL experiments were performed in the Hu20K (in
triplicate). The Sp1 ChIP-DSL experiment was performed in the
Hu2K array (also in triplicate). We classified promoters as ‘‘4’’
when a positive promoter reached p,0.0001 (red cells), as ‘‘3’’
when reached p,0.001 (orange cells), as ‘‘2’’ when reached
p,0.01 (yellow cells), or as ‘‘1’’ when p.0.01 (no binding, green
cells). All results result from co-hybridization of ChIP and input
samples. Note: the Hu20K array contains n = 20,000 promoters,
but we limited our analyses to n = 17,288 promoters after
eliminating n = 2,713 promoters (grey cells in the Excel file) in
which the ChIP-DSL hybridization signal was too low or
unreliable in at least one of the experiments.
(XLSX)
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